current
approv
antivir
therapeut
avail
treatment
prevent
ebola
viru
ebov
infect
studi
character
ebovglycoprotein
gp
pseudotyp
vector
system
differ
cell
cultur
includ
human
umbil
vein
endotheli
cell
huvec
human
macrophag
screen
antiebovgp
agent
base
system
demonstr
aqueou
extract
chpv
chines
herb
prunella
vulgari
display
potent
inhibitori
effect
ebovgp
pseudotyp
viru
ebovgpv
mediat
infect
variou
cell
line
includ
huvec
macrophag
addit
result
indic
chpv
abl
block
egfpexpress
zair
ebola
viru
egfpzebov
infect
cell
antiebov
activ
chpv
exhibit
dosedepend
manner
mgml
concentr
chpv
show
greater
inhibit
ebovgpv
egfpebov
infect
likewis
studi
suggest
inhibitori
effect
chpv
occur
bind
directli
ebovgpv
block
earli
viral
event
interestingli
result
shown
chpv
abl
enhanc
antiebov
activ
monoclon
antibodi
mab
ebovgp
overal
studi
provid
evid
chpv
antiebov
activ
may
develop
novel
antivir
approach
ebov
infect
ebola
viru
ebov
envelop
negativestrand
rna
viru
belong
filovirida
famili
caus
sever
hemorrhag
fever
human
nonhuman
primat
case
fatal
rate
high
ebov
first
identifi
sinc
report
natur
ebola
viru
outbreak
occur
ebola
outbreak
west
africa
largest
caus
death
current
still
effect
treatment
vaccin
ebov
infect
human
therefor
develop
new
antivir
strategi
urgent
global
health
need
ebov
glycoprotein
gp
compris
surfac
unit
transmembran
unit
essenti
compon
viral
envelop
play
central
role
viral
entri
misasi
sullivan
ebov
requir
cell
attach
receptor
interact
requir
membran
fusion
ebovgp
provid
potenti
target
therapeut
strategi
disrupt
ebovgpmedi
viru
entri
block
propag
ebov
vivo
given
filovirus
surfac
glycoprotein
similar
envelop
virus
share
similar
mechan
entri
sever
welldefin
compound
suggest
potenti
inhibit
entri
filovirus
ie
lectin
glucosidas
inhibitor
benzylpiperazin
adamantin
diamid
select
estrogen
receptor
modul
serm
ion
channel
blocker
ie
amiodaron
dronedaron
barton
et
al
e
et
al
chang
et
al
gehr
et
al
johansen
et
al
vincent
et
al
wolf
et
al
howev
compound
propos
antivir
base
vitro
anim
data
investig
effect
safeti
human
still
requir
recent
novel
immunotherapeut
zmapp
consist
combin
monoclon
antibodi
optim
two
previou
antibodi
cocktail
zmab
shown
abl
rescu
rhesu
macaqu
treatment
initi
day
postechalleng
murin
et
al
pettitt
et
al
qiu
et
al
zhang
et
al
monoclon
antibodi
target
interfac
glycan
cap
therebi
inhibit
viral
entri
qiu
et
al
qiu
et
al
ebov
outbreak
western
africa
zmapp
administ
seven
patient
ebola
viru
diseas
evd
unit
state
sever
countri
outcom
consid
statist
signific
mccarthi
moreov
littl
zmapp
antibodi
current
avail
lenni
bernstein
thu
lack
zmapp
unavail
experiment
treatment
affect
region
ebov
outbreak
western
africa
hinder
develop
sourcelimit
countri
tradit
chines
medicin
hold
uniqu
posit
among
tradit
medicin
mani
year
histori
mani
aqueou
extract
tradit
chines
medicin
herb
proven
antivir
activ
zheng
gener
low
toxic
cheap
readili
access
chines
herb
includ
prunella
vulgari
l
panaxginseng
ca
meyer
andrographi
paniculata
lentinu
edod
spirulina
platensi
display
inhibitori
effect
entri
step
variou
virus
hepat
b
chang
et
al
fior
et
al
harada
hayashi
et
al
hayashi
et
al
hayashi
kang
et
al
lee
et
al
li
et
al
liu
et
al
sato
et
al
seubsasana
et
al
tabba
et
al
yao
et
al
yoshida
et
al
zhang
et
al
howev
whether
herb
could
also
inhibitori
activ
ebov
infect
remain
unknown
studi
develop
sensit
ebovgp
pseudotyp
vector
system
screen
antiebov
agent
investig
antivir
mechan
action
base
system
identifi
aqueou
extract
chines
herb
p
vulgari
chpv
abl
inhibit
ebovgpv
egfpebola
viru
infect
bind
ebovgp
block
viral
entri
interestingli
result
also
show
chpv
abl
enhanc
antiebov
activ
monoclon
antibodi
mab
ebovgp
thu
studi
provid
evid
first
time
chpv
aqueou
extract
p
vulgari
potent
antiebov
activ
ebovgp
plasmid
pcaggszebovgp
contain
gene
ebov
glycoprotein
gp
mayinga
strain
gener
clone
full
length
nucleotid
amino
acid
aa
eukaryot
express
vector
pcagg
wahljensen
et
al
lentivir
vector
encod
gaussia
luciferas
gene
plentibasicgluc
purchas
target
system
inc
helper
packag
plasmid
encod
hiv
gagpol
vesicular
stomat
viru
g
vsvg
hivenvelop
plasmid
describ
previous
jayappa
et
al
kobing
et
al
yao
et
al
human
cervic
epitheli
cell
hela
cell
human
lung
carcinoma
cell
human
embryon
kidney
cell
kidney
epitheli
cell
extract
african
green
monkey
cultur
dulbecco
modifi
eagl
medium
two
tlymphoid
cell
line
jurkat
cell
cultur
medium
cell
line
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
except
cell
line
cultur
fb
human
umbil
vein
endotheli
cell
huvec
cultur
media
lonza
contain
fb
hydrocortison
hfgfb
vegf
ascorb
acid
hegf
heparin
huvec
cell
cultur
day
passag
gener
experi
describ
human
pbmc
deriv
macrophag
prepar
dispens
fresh
pbmc
plate
c
h
gentl
wash
dmem
adher
cell
cultur
dmem
contain
fb
ngml
macrophag
colonystimul
factor
mcsf
r
system
day
dna
transfect
cell
perform
standard
calcium
phosphat
precipit
method
mous
monoclon
antibodi
ebov
glycoprotein
monoclon
antibodi
describ
previous
ao
et
al
qiu
et
al
elisa
kit
obtain
aid
vaccin
program
frederick
cancer
research
develop
center
ginsenosid
spirulina
polysaccharid
lentinan
diammonium
glycyrrhizin
dg
obtain
chines
compani
en
bang
biotech
co
yuchang
biotech
inc
luy
pharma
group
ltd
china
taitianq
pharmaceut
ltd
andrographolid
purchas
sigma
inc
dri
fruitspik
p
vulgari
l
labiata
purchas
tong
ren
tang
health
pharmaceut
co
ltd
beij
cn
herb
extract
process
base
method
describ
previous
yao
et
al
briefli
dri
herb
soak
overnight
deioniz
water
room
temperatur
boil
h
centrifug
g
min
supernat
filter
mm
cellulos
acet
membran
lyophil
result
dark
brown
residu
dissolv
deioniz
water
store
c
singl
symmetr
peak
correspond
molecular
weight
polysaccharid
approxim
kda
aqueou
extract
pv
detect
hplc
analysi
describ
previous
yao
et
al
ebovgp
pseudovirion
ebovgpv
produc
transfect
cell
pcaggszebovgp
mg
mg
plentibasicgluc
plasmid
mg
meanwhil
vsvg
hiv
env
pseudovirion
produc
cell
transfect
vsvg
hiv
env
plasmid
togeth
plentibasicgluc
plasmid
hr
posttransfect
cell
cultur
supernat
collect
pseudovirion
purifi
supernat
ultracentrifug
rpm
h
pellet
virus
resuspend
dmem
medium
viru
titer
quantifi
use
elisa
assay
pseudovirion
quantifi
measur
viralassoci
hiv
level
use
elisa
assay
amount
ebovgpv
vsvg
hiv
env
pseudovirion
adjust
level
incub
target
cell
per
well
well
plate
cell
per
well
well
plate
h
wash
medium
h
supernat
collect
viral
infect
evalu
measur
gaussia
luciferas
gluc
activ
briefli
coelenterazin
substrat
nanolight
technolog
ad
supernat
mix
well
read
luminomet
promega
usa
test
antiebov
entri
activ
chines
herb
variou
concentr
herb
extract
compound
mix
ebovgpv
directli
ad
target
cell
differ
time
point
h
infect
c
cell
wash
twice
medium
remov
excess
residu
virus
herb
extractcompound
antiebov
activ
evalu
measur
gluc
activ
cultur
supernat
differ
time
point
infect
similarli
analysi
inhibitori
effect
mab
chpv
seri
dilut
alon
combin
vari
concentr
chpv
mix
ebovgpv
ad
cell
macrophag
h
incub
cell
wash
gluc
activ
cell
cultur
supernat
detect
h
postinfect
macrophag
studi
continu
exposur
chpv
pseudovirion
treatment
also
perform
briefli
chpv
ad
h
cell
prior
infect
follow
ebovgpv
infect
without
mab
infect
cell
cultur
medium
contain
chpvebovgpv
mab
without
wash
gluc
activ
cell
cultur
supernat
monitor
h
postinfect
zair
ebola
viru
zebov
infect
util
recombin
zebov
express
enhanc
green
fluoresc
protein
egfp
name
egfpzebov
viru
show
similar
phenotyp
wildtyp
zebov
wtzebov
vitro
produc
mild
diseas
rhesu
macaqu
lethal
mice
lack
signal
transduc
activ
transcript
even
moder
attenu
compar
caus
wtzebov
ebihara
et
al
viru
stock
prepar
describ
previous
qiu
et
al
test
inhibitori
effect
chpv
egfpzebov
infect
first
ad
differ
amount
chpv
orand
mab
cell
min
cell
infect
approxim
pfu
egfpzebov
presenc
chpv
mab
h
infect
cell
wash
cultur
fresh
medium
without
drug
h
infect
cell
fix
phosphatebuff
formalin
fluoresc
plaqu
count
use
aid
fluoresc
plate
reader
describ
previous
patel
et
al
test
bind
chpv
ebovgpv
ebovgpv
mix
chpv
mab
medium
alon
incub
min
c
treat
ebovgpv
collect
ultracentrifug
beckman
rotor
rpm
h
pellet
pseudovirion
resuspend
fresh
dmem
use
infect
cell
infect
monitor
measur
gluc
activ
supernat
h
infect
detect
viral
attach
cell
presenc
chpv
cell
well
plate
first
cool
ice
min
ebovgpv
ng
ad
absenc
presenc
indic
concentr
chpv
h
incub
ice
cell
wash
cold
pb
remov
unbound
viru
lyse
ripa
lysi
buffer
viru
attach
cell
detect
elisa
assay
cell
prolifer
assay
roch
use
determin
cytotox
chpv
describ
earlier
ao
et
al
briefli
huvec
cultur
cellswel
plate
treat
chpv
h
h
ad
cultur
mlwell
incub
c
h
absorb
measur
nm
use
micropl
reader
gener
ebovgp
pseudovirion
ebovgpv
ebovgpexpress
plasmid
pcaggszebovgp
cotransfect
hivbas
lentivir
vector
encod
gaussia
luciferas
gene
packag
plasmid
cell
fig
parallel
hiv
pseudovirion
virus
without
envelop
glycoprotein
includ
control
gaussia
luciferas
gluc
bioluminesc
enzym
secret
cell
cultur
media
enabl
analysi
viral
replic
direct
measur
gluc
activ
supernat
examin
express
incorpor
ebovgp
cell
viru
virusproduc
cell
viru
lysat
analyz
sdspage
western
blot
mous
indic
fig
pregp
kda
kda
clearli
detect
ebovgptransfect
cell
fig
lane
molecular
mass
correspond
previous
describ
ebovgp
elliott
et
al
volchkov
et
al
volchkov
et
al
expect
abund
detect
ebovgpv
indic
ebovgp
effici
incorpor
pseudovirion
fig
lane
meanwhil
hiv
capsid
protein
detect
cell
lysat
pellet
ebovgpv
virion
without
envelop
protein
rabbit
antibodi
fig
lower
panel
test
whether
ebovgpv
abl
infect
cell
equal
amount
ebovgpv
viral
particl
without
envelop
protein
adjust
hiv
incub
cell
h
gluc
activ
supernat
measur
evalu
viru
infect
h
postinfect
result
indic
ebovgpv
abl
effici
infect
cell
wherea
viral
particl
without
viral
envelop
protein
produc
gluc
activ
fig
test
whether
pseudovirion
infect
mediat
ebovgp
previous
describ
monoclon
antibodi
mab
target
ebola
viru
glycoprotein
qiu
et
al
qiu
et
al
use
block
entri
ebovgpv
briefli
ebovgpv
incub
variou
dilut
min
ad
onto
cell
h
postinfect
pi
gluc
activ
measur
result
show
ebovgpv
infect
cell
could
effici
block
dosedepend
manner
fig
inhibit
infect
achiev
use
concentr
mgml
result
clearli
indic
ebovgp
respons
entri
pseudovirion
infect
abil
ebovgpv
infect
cell
type
analyz
differ
cell
line
includ
cell
cell
human
cervic
epitheli
cell
hela
tlymphoid
cell
jurkat
cell
huvec
human
lung
carcinoma
cell
fig
parallel
amount
hivenv
pseudovirion
hivenvv
vsvg
pseudovirion
vsvgev
use
control
gluc
activ
test
supernat
h
pi
expect
vsvgev
effici
infect
target
cell
line
wherea
hivenvv
target
cell
includ
jurkat
cell
contrast
ebovgpv
unabl
induc
detect
level
gluc
activ
jurkat
tlymphoid
cell
agreement
previous
describ
ebovgp
tropism
rang
woollewi
bate
ebovgpv
shown
abl
infect
human
hela
cell
cell
human
cell
primari
huvec
result
clearli
distinguish
differ
tropism
ebovgp
hiv
vsvg
envelop
protein
previou
studi
demonstr
ebovgpv
mediat
ebovgpspecif
viral
entri
viral
replic
easili
detect
measur
gluc
activ
supernat
use
system
next
test
effect
differ
chines
herb
ebov
entri
number
studi
suggest
extract
chines
herb
display
signific
inhibitori
effect
entri
andor
replic
differ
virus
tabl
therefor
studi
chpv
ginsenosid
andrographolid
spirulina
polysaccharid
lentinan
diammonium
glycyrrhizin
extract
p
vulgari
well
panaxginseng
andrographi
paniculata
spirulina
platensi
lentinu
edod
liquoric
assess
potenti
antiebov
activ
cytotox
studi
show
none
extract
obviou
cytotox
effect
cell
concentr
mgml
data
shown
therefor
use
serial
dilut
chpv
mgml
mgml
h
infect
ebovgpv
presenc
herb
infect
cell
wash
remov
residu
pseudovirion
herb
gluc
activ
supernat
measur
h
pi
result
show
presenc
andrographolid
spirulina
polysaccharid
ebovgpv
still
replic
effici
suggest
herb
affect
replic
gp
pseudotyp
viru
fig
contrast
chpv
show
strong
inhibitori
effect
ebovgpv
infect
approxim
inhibit
ebovgpv
infect
achiev
chpv
use
mgml
fig
ginsenosid
also
display
modest
antivir
effect
higher
concentr
mgml
thu
continu
character
antiebov
activ
chpv
mode
action
gain
insight
mechan
chpv
inhibit
ebovgpv
infect
consist
concentr
chpv
mgml
ad
cell
cultur
medium
variou
time
point
includ
pre
simultan
postexposur
cell
ebovgppseudovirion
result
fig
show
cell
pretreat
chpv
h
remov
ad
pseudovirion
inhibitori
effect
viru
infect
fig
suggest
inhibitori
activ
chpv
act
directli
cell
render
resist
infect
interestingli
cell
incub
simultan
ebovgpv
chpv
strong
inhibitori
effect
achiev
neg
impact
viral
infect
chpv
ad
hr
postinfect
fig
result
reveal
chpv
block
ebovgpv
replic
earli
step
infect
also
led
us
believ
major
inhibitori
effect
chpv
may
action
viru
shown
fig
ebovgpv
first
incub
chpv
mgml
min
c
chpvtreat
virus
pellet
ultracentrifug
wash
media
remov
residu
unbound
chpv
fig
control
ebovgpv
incub
antiebovgp
antibodi
media
alon
pellet
ultracentrifug
pellet
virus
use
infect
cell
gluc
activ
measur
h
postinfect
similar
pseudovirion
incub
pseudovirion
pretreat
chpv
also
display
signific
reduct
infect
abil
compar
pseudovirion
incub
medium
alon
fig
exclud
possibl
free
solubl
activ
constitu
chpv
could
pellet
ultracentrifug
rather
associ
viru
perform
ultracentrifug
procedur
chpv
alon
centrifug
supernat
resuspend
pellet
sampl
ad
cell
follow
ebovgpv
infect
shown
fig
chpv
supernat
ultracentrifug
still
show
strong
antivir
activ
compar
ebovgpv
infect
absenc
chpv
contrast
pellet
portion
exert
antivir
activ
fig
indic
solubl
activ
constitu
chpv
could
pellet
result
suggest
chpv
might
attach
viral
glycoprotein
consequ
block
viral
entri
howev
could
still
rule
possibl
presenc
chpv
may
also
result
conform
chang
ebovgp
determin
chpv
directli
interf
viral
adsorpt
process
interact
viru
cell
attach
ebov
gpv
assess
measur
cellassoci
pseudovirion
elisa
assay
briefli
cell
cool
ice
min
ebov
gpv
presenc
absenc
chpv
mgml
ad
h
incub
ice
cell
wash
cold
pb
remov
unbound
viru
lyse
ripa
buffer
cellbound
pseudovirion
measur
detect
level
cell
lysat
result
show
pseudovirion
incub
continu
dilut
chpv
amount
cellassoci
increas
dosedepend
manner
fig
ugml
chpv
could
block
approxim
pseudovirion
attach
result
clearli
indic
chpv
could
interfer
viru
attach
cell
consequ
prevent
viru
entri
welldocu
dysregul
endotheli
cell
purifi
bioactiv
extract
p
vulgari
l
fruitspik
prevent
hiv
attach
receptor
suppress
entri
disrupt
sixhelix
bundl
format
inactiv
directli
block
bind
vero
cell
inhibit
penetr
vero
cell
liu
et
al
tabba
et
al
yao
et
al
zhang
et
al
ginsenosid
ginsenosid
class
steroid
glycosid
purifi
panaxginseng
ca
meyer
ginsenosid
effect
antihepat
b
viru
activ
mediat
interrupt
viru
adsorpt
host
cell
dna
replic
secret
hepat
b
surfac
antigen
kang
et
al
lee
et
al
li
et
al
andrographolid
major
bioactiv
chemic
constitu
andrographi
paniculata
andrographolid
report
antihiv
activ
vitro
inhibitori
effect
compound
viral
entri
replic
step
chang
et
al
seubsasana
et
al
spirulina
polysaccharid
natur
sulfat
polysaccharid
isol
spirulina
platensi
spirulina
polysaccharid
shown
target
viral
absorpt
penetr
stage
replic
stage
penetr
cell
hayashi
et
al
hayashi
hayashi
et
al
lentinan
polysaccharid
isol
common
edibl
mushroom
lentinu
edod
sulfat
lentinan
exhibit
potent
antihiv
activ
suppress
viral
adsorpt
cell
revers
transcriptas
yoshida
et
al
diammonium
glycyrrhizin
dg
dg
extract
purifi
liquoric
radix
glycyrrhiza
antihepat
b
viru
reduc
transport
membran
sialyl
hepat
b
viru
surfac
antigen
antihiv
reduct
membran
fluiditi
lend
inhibit
fusion
antivir
activ
sar
relat
coronaviru
respiratori
syncyti
viru
arbovirus
vaccinia
viru
vesicular
stomat
viru
also
reveal
vitro
studi
fior
et
al
harada
sato
et
al
function
ebov
infect
induc
wide
rang
vascular
effect
caus
chang
vascular
permeabl
hemorrhag
dvorak
et
al
kevil
et
al
studi
suggest
ebovgp
main
determin
vascular
cell
injuri
yang
et
al
yang
et
al
demonstr
fig
huvec
extrem
sensit
ebov
therefor
choos
primari
huvec
target
cell
evalu
chpv
could
also
protect
huvec
ebovgp
infect
briefli
variou
concentr
chpv
mix
ebovgpv
ad
immedi
onto
huvec
h
postinfect
cell
wash
cultur
medium
without
herb
expect
upon
increas
concentr
chpv
gluc
activ
ebovgpvinfect
huvec
decreas
dosedepend
manner
fig
indic
ebovgpv
infect
huvec
specif
block
chpv
mgml
chpv
use
less
gluc
activ
could
detect
meanwhil
fig
show
cell
viabil
treatment
differ
concentr
chpv
h
h
measur
cell
prolifer
assay
h
chpv
treatment
group
detect
cytotox
concentr
mgml
h
continu
chpv
treatment
group
huvec
grew
normal
concentr
mgml
well
known
macrophag
major
initi
target
cell
ebola
viru
infect
macrophag
attract
target
cell
induc
increas
vasodilat
vascular
permeabl
dissemin
intravascular
coagul
produc
proinflammatori
cytokin
chemokin
bray
geisbert
therefor
necessari
evalu
inhibitori
effect
chpv
ebovgpv
infect
macrophag
first
test
effect
chpv
incub
human
primari
macrophag
chpv
ebovgpv
h
shown
fig
bar
right
side
gluc
activ
supernat
infect
macrophag
significantli
decreas
h
presenc
chpv
mgml
also
infect
macrophag
presenc
chpv
maintain
macrophag
medium
contain
ebovgpv
chpv
h
without
wash
case
ebovgpv
infect
inhibit
chpv
inhibit
rate
high
compar
posit
control
fig
left
bar
suggest
optimum
inhibitori
effect
chpv
could
obtain
continu
presenc
chpv
cultur
medium
addit
observ
cytotox
effect
mgml
chpv
present
macrophag
cultur
h
data
shown
describ
ebovgpspecif
monoclon
antibodi
fig
chpv
fig
could
effici
block
viral
entri
step
next
ask
whether
stronger
inhibitori
effect
could
achiev
combin
chpv
mab
rel
lower
concentr
fig
serial
dilut
mgml
mgml
concentr
combin
indic
concentr
chpv
mgml
result
show
viral
infect
reduc
approxim
concentr
chpv
mgml
interestingli
greater
inhibitori
effect
achiev
chpv
mgml
combin
concentr
mgml
addit
effect
evid
lower
concentr
mgml
chpv
combin
differ
dose
exampl
mgml
mgml
chpv
ad
alon
inhibit
obtain
respect
two
drug
ad
togeth
concentr
inhibit
observ
clearli
indic
much
stronger
inhibit
could
achiev
combin
use
chpv
oppos
use
treatment
alon
obviou
achiev
level
inhibit
mab
dosag
could
reduc
presenc
chpv
similar
phenomenon
observ
macrophag
h
postinfect
pseudovirion
presenc
chpv
presenc
absenc
macrophag
fig
combin
chpv
mgml
mgml
could
decreas
infect
ebovgpv
compar
chpv
mgml
mgml
alon
remark
chpv
ad
h
infect
amount
chpv
maintain
cours
infect
infect
ebovgpv
complet
inhibit
fig
given
chpv
abl
block
ebovgpmedi
pseudovirion
entri
next
question
ask
whether
chpv
could
block
zebov
infect
address
question
perform
egfpzebov
infect
presenc
chpv
antibodi
cell
briefli
differ
concentr
chpv
antibodi
ad
cell
cultur
min
cell
infect
pfu
egfpzebov
presenc
concentr
chpv
h
infect
cell
wash
cultur
fresh
medium
without
drug
h
postinfect
observ
cphvinduc
toxic
effect
cell
cell
fix
phosphatebuff
formalin
fluoresc
plaqu
count
use
aid
fluoresc
plate
reader
remark
result
reveal
presenc
ugml
chpv
reduc
egfpzebov
infect
presenc
ug
ml
chpv
egfpzebov
infect
inhibit
approxim
fig
agreement
previou
report
also
show
strong
block
effect
ebola
viru
infect
qiu
et
al
mgml
concentr
antibodi
approxim
viru
infect
block
fig
result
provid
strong
evid
chpv
abl
inhibit
ebov
infect
test
whether
combin
use
chpv
could
enhanc
antiebov
infect
activ
treat
cell
alon
plu
chpv
cell
egfp
g
infect
pellet
pseudovirion
test
ad
cell
gluc
activ
h
shown
rel
ratio
compar
viru
incub
dmem
pc
ebovgpv
treat
drug
amount
chpv
ultracentrifug
result
supernat
pellet
incub
ebovgpv
ad
cell
gluc
activ
h
shown
percentag
control
activ
result
mean
valu
standard
deviat
sd
three
independ
experi
e
chpv
block
attach
ebovgpv
amount
ebovgpv
ng
variou
concentr
chpv
ad
cell
ice
h
sampl
without
pseudovirion
chpv
treatment
use
neg
control
cell
wash
cold
pb
remov
unbound
viru
lyse
ripa
buffer
virus
attach
cell
monitor
measur
hiv
antigen
level
elisa
zebov
infect
describ
h
infect
cell
fix
phosphatebuff
formalin
inhibitori
effect
chpv
presenc
absenc
macrophag
posit
control
pc
infect
macrophag
absenc
chpv
ebovgpv
mix
chpv
ugml
presenc
absenc
ugml
immedi
ad
onto
cell
cultur
follow
wash
cell
h
incub
cell
cultur
medium
without
chpv
supernat
collect
h
postinfect
use
detect
gluc
activ
major
scale
yaxi
left
right
differ
unit
unit
respect
c
amount
ebovgpv
presenc
absenc
ugml
ad
onto
chpv
mgml
preincub
h
macrophag
amount
chpv
without
ugml
maintain
cours
infect
posit
control
pc
infect
macrophag
absenc
chpv
supernat
collect
gluc
activ
test
h
continu
cultur
without
wash
major
scale
base
yaxi
unit
left
unit
right
fluoresc
plaqu
count
use
aid
fluoresc
plate
reader
interestingli
combin
treatment
potenti
inhibit
egfpzebov
infect
fig
result
reveal
treatment
ugml
alon
reduc
egfpzebov
infect
approxim
respect
presenc
mg
mg
ugml
reduc
egfpzebov
infect
approxim
respect
compar
egfpzebov
infect
absenc
antibodi
chpv
fig
indic
combin
treatment
chpv
ebov
infect
could
achiev
better
inhibitori
effect
viral
infect
due
fact
ebov
classifi
biosafeti
level
pathogen
studi
replic
well
test
antiebov
drug
requir
biosafeti
level
contain
procedur
significantli
limit
ebovrel
research
activ
mani
microbiolog
laboratori
overcom
limit
sever
previou
studi
examin
use
ebovgp
pseudotyp
viral
vector
environ
includ
replicationdefect
mlv
hiv
replicationcompet
vesicular
stomat
viru
newcastl
diseas
viru
investig
ebovgpmedi
viru
entri
mechan
screen
new
therapeut
agent
basu
et
al
dinapoli
et
al
takada
et
al
wen
et
al
wong
et
al
woollewi
bate
yang
et
al
yonezawa
et
al
studi
entri
pseudotyp
viruslik
particl
monitor
use
enzym
biolog
marker
express
pseudovirion
gain
entri
cell
studi
use
sensit
ebolagpmedi
hivbas
vector
system
contain
gaussia
luciferas
gluc
gene
report
fig
gluc
secret
supernat
express
assay
make
practic
evalu
quantifi
level
ebovgpmedi
viru
entri
use
antiebolagp
drug
screen
environ
result
demonstr
infect
ebovgpv
requir
function
ebovgpmedi
cell
entri
neutral
mab
specif
ebovgp
fig
use
ebovgpmedi
viru
entri
system
test
sever
chines
herb
extract
shown
aqueou
extract
p
vulgari
chpv
exhibit
potent
inhibitori
activ
ebovgp
viru
entri
extract
test
fig
remark
chpv
could
effici
inhibit
infect
ebovgp
pseudovirion
primari
target
cell
human
macrophag
inhibit
rate
reach
high
chpv
ugml
continu
present
cultur
medium
fig
concentr
chpv
could
inhibit
approxim
viral
infect
huvec
even
cell
treat
h
chpv
viru
ad
soon
fig
moreov
studi
clearli
shown
ugml
chpv
reduc
wild
type
ebov
infect
presenc
mg
chpv
ebov
viru
infect
inhibit
fig
observ
provid
convinc
evid
chpv
potenti
agent
ebov
deserv
investig
anim
studi
investig
chpv
antiebov
mechan
action
timeofaddit
studi
perform
chpv
identifi
block
ebovgpv
infect
possibl
suppress
viru
attach
target
viral
gp
protein
fig
previou
studi
demonstr
aqueou
extract
pv
decreas
replic
herp
simplex
viru
hsv
prevent
viru
bind
cell
chiu
et
al
zhang
et
al
inhibit
infect
prevent
viral
attach
cell
receptor
oh
et
al
tabba
et
al
yao
et
al
suggest
chpv
target
invari
compon
among
virus
fact
suggest
antivir
activ
chpv
might
relat
anion
polysaccharid
polysaccharid
form
complex
viru
protein
like
occur
mainli
format
salt
linkag
ion
pair
opposit
charg
group
polym
viru
protein
ultim
block
viru
entri
izumi
et
al
exampl
well
establish
sulfat
polysaccharid
select
interact
polycation
loop
highli
basic
region
huang
et
al
interfer
attach
hiv
cellsurfac
receptor
harrop
rider
moulard
et
al
vive
et
al
whether
polyanion
properti
respons
viral
entri
inhibit
mechan
chpv
remain
determin
howev
point
also
could
rule
possibl
presenc
chpv
might
also
result
conform
chang
ebovgp
render
unabl
interact
receptor
requir
investig
question
specif
antivir
activ
chpv
whether
chpv
act
virus
envelop
virus
still
remain
unansw
concentr
chpv
dilut
begin
mgml
mgml
start
mgml
follow
dilut
mgml
indic
concentr
chpv
mab
alon
ad
cell
differ
concentr
chpv
mab
mix
indic
ad
cell
b
exposur
cell
pfu
egfpzebov
incub
h
medium
chang
fresh
medium
h
later
cell
fix
phosphatebuff
formalin
fluoresc
plaqu
count
use
aid
fluoresc
plate
reader
error
bar
repres
variat
triplic
sampl
data
b
repres
result
obtain
two
independ
experi
previou
report
shown
polysaccharid
p
vulgari
ugml
activ
herp
simplex
viru
type
unabl
inhibit
cytomegaloviru
cmv
human
influenza
viru
type
b
polioviru
type
vesicular
stomat
viru
vsv
xu
et
al
consist
data
also
indic
chpv
could
inhibit
vsvg
pseudovirion
infect
data
shown
thu
chpv
action
appear
specif
certain
viru
speci
addit
data
also
reveal
chpv
act
cell
surfac
chang
suscept
hiv
yao
et
al
ebov
fig
thu
observ
suggest
specif
antivir
effect
chpv
howev
underli
molecular
mechan
requir
investig
anoth
interest
observ
studi
combin
antiebov
antibodi
chpv
could
enhanc
antiebov
activ
antibodi
first
report
qiu
et
al
qiu
et
al
crucial
compon
two
antibodi
cocktail
zmab
zmapp
mab
show
great
potenti
block
ebov
infect
vitro
anim
studi
qiu
et
al
qiu
et
al
qiu
et
al
recent
zmapp
approv
februari
clinic
trial
liberia
unit
state
albayati
et
al
one
disadvantag
use
mab
antiebov
agent
sourc
limit
especi
resourceconstrain
geograph
region
outbreak
filoviru
infect
frequent
occur
therefor
discoveri
agent
capabl
prevent
ebov
viru
infect
contribut
enhanc
mabmedi
antiebov
effect
need
investig
whether
presenc
chpv
togeth
would
demonstr
stronger
antiebov
effect
result
show
combin
use
lower
concentr
chpv
could
achiev
antiebovgp
effici
high
concentr
alon
fig
reason
might
due
combin
effect
differ
bind
mechan
monoclon
antibodi
known
bind
fusion
loop
import
viral
entri
qiu
et
al
contrast
action
chpv
specul
target
due
mucinlik
domain
respons
viral
attach
lin
et
al
simmon
et
al
simmon
et
al
takada
et
al
fact
chpv
exert
effect
attach
viru
cell
addit
could
exclud
possibl
chpv
may
also
bind
fusion
region
requir
investig
combin
effect
signific
similar
effici
would
achiev
use
reduc
amount
antibodi
chpv
ii
combin
chpv
reduc
likelihood
viral
resist
iii
therapeut
window
could
extend
continu
use
chpv
infect
individu
addit
mani
studi
demonstr
aqueou
extract
contain
mani
compon
immunomodulatori
effect
ahn
et
al
fang
et
al
fang
et
al
psotova
et
al
ryu
et
al
shin
et
al
sun
et
al
et
al
also
possibl
chpv
could
combin
sever
activ
ingredi
requir
investig
thu
asid
directli
antiebov
effect
chpv
might
also
great
potenti
immunomodul
suppress
sever
upset
disord
immun
cell
prolifer
contract
caus
ebov
infect
extend
antibodi
therapeut
window
overal
demonstr
chpv
act
ebov
entri
inhibitor
could
enhanc
inhibitori
activ
ebov
mab
natur
plant
extract
merit
investig
promis
antivir
due
rich
sourc
low
cost
low
cytotox
wide
accept
strong
antivir
properti
addit
detail
chemic
research
identifi
purifi
activ
ingredi
facilit
mechanist
analys
applic
